A late-stage study of Johnson & Johnson’s COVID-19 vaccine candidate has been paused while the company investigates whether a study participant’s “unexplained illness” is related to the shot.
The company said in a statement Monday evening that illnesses, accidents, and other so-called adverse events “are an expected part of any clinical study, especially large studies,” but that its physicians and a safety monitoring panel would try to determine what might have caused the illness.
The pause is at least the second such hold to occur among several vaccines that have reached large-scale final tests in the U.S.
The company declined to reveal any more details about the illness, citing the participant’s privacy.
Temporary stoppages of large medical studies are relatively common. Few are made public in typical drug trials, but the work to make a coronavirus vaccine has raised the stakes on these kinds of complications.
Companies are required to investigate any serious or unexpected reaction that occurs during drug testing. Given that such tests are done on tens of thousands of people, some medical problems are a coincidence. In fact, one of the first steps the company said it will take is to determine if the person received the vaccine or a placebo.
The halt was first reported by the health news site STAT.
Final-stage testing of a vaccine made by AstraZeneca and Oxford University remains on hold in the U.S. as officials examine whether an illness in its trial poses a safety risk. That trial was stopped when a woman developed severe neurological symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord, the company has said. That company's testing has restarted elsewhere.
Johnson & Johnson was aiming to enroll 60,000 volunteers to prove if its single-dose approach is safe and protects against the coronavirus. Other vaccine candidates in the U.S. require two shots.
Salary is usually the deciding factor in a job search. Cheddar News' docuseries, "Ready 4 Work," highlights this and much more as it follows six people on their job-hunting journeys and how income is the main goal.
The Federal Trade Commission has begun notifying people that they may be entitled to some claims from Fortnite after a settlement from alleged deceptive business practices.
The Federal Reserve continues to meet over monetary policy but is expected to hold rates steady.
Eli Lilly is suing 10 medical spas, wellness clinics and compounding pharmacies across the country for allegedly selling cheaper counterfeit drugs.
Brenda LaManna, founder and president of Damselfly Flowers, and Warren Schorr, senior vice president with Crayola, joined Cheddar News to discuss how and why the famous Crayon company is launching an online flower business.
Ed Egilinsky, managing director and head of sales and distribution and alternative with Direxion, joined Cheddar News to discuss how short-term traders are preparing for any forward-looking guidance from the Federal Reserve about any potential rate hikes. Egilinsky also discussed how traders are looking at the overall banking sector for the short-term.
Mark Spoonauer, global editor-in-chief with Tom's Guide, joined Cheddar News to get a sneak peek at some of Apple's new products that are set to be released to the general public, including the iPhone 15 and Apple Watch.
Stocks rose Wednesday ahead of the Federal Reserve's continued two-day meeting on its monetary policy.
Kraft Heinz said Tuesday it's recalling more than 83,000 cases of individually-wrapped Kraft Singles American processed cheese slices because part of the wrapper could stick to the slice and become a choking hazard.
California regulators on Tuesday ordered one of the country’s oldest bottled water brands to stop using some of the natural springs it has relied on for more than 100 years to market its products throughout the western U.S.
